INTRODUCTION
Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells (HSPCs) characterized by enhanced proliferation and impaired differentiation. Recurrent mutations in transcription factors (TFs) and epigenetic regulators identified in AML (Dö hner et al., 2015; Cancer Genome Atlas Research Network, 2013) suggest that aberrant transcriptional circuits are a common feature of leukemogenesis. Collectively, these circuits drive oncogenic gene expression programs that inhibit differentiation and activate self-renewal, generating leukemia stem cells (LSCs) responsible for the initiation and propagation of disease (Chao et al., 2008; Reya et al., 2001; Somervaille and Cleary, 2006) .
In leukemias with rearrangements of the Mixed Lineage Leukemia (MLL) gene, activation of a self-renewal circuit involving the Hox gene cluster is a key aspect in the transformation of committed myeloid progenitor cells . Studies have identified multiple transcription factor dependencies within this circuitry, including HoxA9, Meis1, b-catenin, Myc, and Myb, demonstrating that re-wired transcriptional circuits in LSCs may be targeted by blocking the activity of single TFs (Faber et al., 2009; Wang et al., 2010; Wong et al., 2007; Zuber et al., 2011a) . Although both LSCs and normal hematopoietic stem cells (HSCs) share the hallmark feature of self-renewal, differences in their transcriptional wiring and the degree of functional redundancy within their stemness circuits may offer selective therapeutic opportunities (Huntly and Gilliland, 2005; Novershtern et al., 2011) .
Recent studies demonstrate that leukemia-specific targets may be identified using short-hairpin RNA (shRNA) screens to interrogate multiple genes in primary AML cells in vivo (Jä rå s et al., 2014; Miller et al., 2013; Zuber et al., 2011b) . These screens employ disease models that reflect the phenotypic and functional cellular heterogeneity observed in human AML (Lapidot et al., 1994) and aim to study leukemia cells in the context of the niche (Lane et al., 2009; Schepers et al., 2015) . In vivo screening using primary cell models enables the identification of both cell autonomous and cell non-autonomous mechanisms relevant to disease biology. We, therefore, used pooled, in vivo shRNA screening to identify transcription factor dependencies in leukemia stem cells.
RESULTS

Pooled In Vivo RNA Interference Screening in LSCs
To identify essential TFs in leukemia and to highlight transcriptional mechanisms of self-renewal in LSCs, we performed an in vivo RNAi screen using a serial transplantation model of MLL-AF9-driven, myelomonocytic AML derived from dsRed + mice ( Figure S1A ). LSCs in this model are aggressive, immunophenotypically defined, and may be enriched by prospectively sorting dsRed-labeled cells with high expression of the c-Kit cell surface marker ) ( Figure S1B ). The short-latency, high penetrance quaternary transplant leukemias are highly enriched for LSCs and are suitable for in vivo screening . Given the limited number of genes that can be effectively examined in such an in vivo screen, we first identified candidate TFs on the basis of gene expression (Bullinger et al., 2004; Chen et al., 2008; Krivtsov et al., 2009; Metzeler et al., 2008; Novershtern et al., 2011; Somervaille et al., 2009; Valk et al., 2004; Wang et al., 2010) . We selected DNA-binding proteins that have higher expression in stem cells (LSCs or HSCs) compared to myeloid progenitor cells and are co-expressed with the canonical LSC regulators HoxA9 and Meis1. The top 152 genes, based on this analysis, were selected for the screen (Table S1A) .
To test the functional importance of these candidate genes, we generated a custom pool of 770 lentiviral shRNAs (approximately five shRNAs per gene) and seven control shRNAs that lack complementarity with any known murine genes. Freshly sorted quaternary transplant leukemia cells were transduced with six subpools of lentiviral shRNAs. An aliquot of these cells was banked 24 hr later, and the remainder was transplanted to sublethally irradiated mice (five replicate mice per subpool). Two weeks after transplantation, leukemia cells were banked from the bone marrow of moribund recipient mice ( Figure S1C ). Genomic DNA was harvested from both banks of cells and shRNAs were PCR amplified and sequenced on the Illumina platform (Moffat et al., 2006) .
We compared the quantitative representation of shRNAs in the input and leukemic bone marrow samples and observed strong concordance between biological replicates (Figures 1A and S1D). We identified 35 transcriptional regulators targeted by at least three shRNAs depleted >20-fold (Table S1B) , indicating that these genes are essential for AML cells in vivo. Top hits from the screen are established regulators of LSC function, including HoxA9, Meis1, b-catenin, Pbx1, and Myc ( Figure 1B ). Other genes that scored are implicated in myeloid specification (PU.1), Myc activity (Mlxip), PML bodies (Pml, Mzf1, Trim27, Rere), Mef2c signaling (Mef2c, Foxj3) , and the circadian rhythm (Clock and Bmal1). For key hits, we validated that top scoring shRNAs effectively decrease expression of their target gene ( Figure S1E ).
Clock and Bmal1 Are Required for Leukemia Cell Growth Two hits from our in vivo screen were Clock and Bmal1, encoding basic helix-loop-helix (bHLH) domain-containing TFs that regulate transcription as a heterodimer . Multiple shRNAs targeting Clock or Bmal1 were depleted >20-fold in vivo, with several shRNAs depleted up to 1,000-fold ( Figure 1B) . Clock and Bmal1, and their Period (Per1, Per2, Per3) and Cryptochrome (Cry1, Cry2) target genes, are core components of a transcriptional-translational feedback loop that drives rhythmic gene expression to regulate circadian physiology (Partch et al., 2014; Wager-Smith and Kay, 2000) . Following activation of Per and Cry gene expression, Per:Cry heterodimers feedback repress Clock:Bmal1 activity, resulting in an autoregulatory loop that is completed in approximately 24 hr. In the hematopoietic system, the circadian clock regulates HSC egress from the bone marrow microenvironment (Mé ndez-Ferrer et al., 2008) , hematopoietic engraftment (D'Hondt et al., 2004; Rolls et al., 2015) , and bone marrow mitotic activity (Clark and Korst, 1969; Smaaland et al., 1991) . Cell autonomous and cell non-autonomous functions of the circadian rhythm in leukemia have not been rigorously established.
We validated a role for Clock and Bmal1 in leukemia in vivo with shRNAs co-expressed with GFP from single lentiviral vectors. We transduced murine MLL-AF9 leukemia cells with individual shRNAs, transplanted the cells to sublethally irradiated recipient mice, and compared the percentage of GFP + leukemia cells before transplant and after 2 weeks in vivo. GFP + cells expressing Clock or Bmal1 shRNAs were strongly depleted in vivo, while cells expressing the luciferase (Luc) control shRNA were stable over time ( Figure 1C ). To evaluate whether this effect is independent of the bone marrow microenvironment or cell engraftment, we performed an equivalent experiment in vitro with cytokine supplementation (IL3, IL6, and SCF). Similar to the phenotype in vivo, GFP + cells were depleted over 12 days in culture following transduction with Clock or Bmal1 shRNAs but not with the Luc control ( Figure 1D ). To account for possible off-target effects of the shRNAs, we performed a cDNA rescue experiment. We generated a retroviral vector that co-expresses GFP and a mutant Bmal1 cDNA with silent point mutations in the shRNA binding sites. We sequentially transduced murine leukemia cells with the rescue vector and Bmal1 shRNAs, followed by puromycin selection of shRNA-expressing cells. In this experiment, an increase in the percentage of GFP + cells reflects selection for the shRNA-resistant Bmal1 cDNA and confirms on-target effects. Indeed, we observed a significant increase in the GFP + fraction in vitro for two Bmal1 shRNAs (A1, A6) normalized to the Luc control ( Figure 1E ).
As an added confirmation of specificity, we used CRISPRCas9-based genome editing to introduce loss-of-function mutations in the Bmal1 gene in primary murine leukemia cells. We transduced quaternary transplant MLL-AF9 cells with lentiviral SFFV-driven Cas9 followed by puromycin selection of cells with stable Cas9 expression (Heckl et al., 2014) . Leukemia cells were then transduced with a separate lentiviral vector that co-expresses RFP657 and a single guide RNA (sgRNA) targeting luciferase, Bmal1, or HoxA9 as a positive control. Consistent with the shRNA results, an sgRNA targeting Bmal1 was progressively depleted ( Figures 1F, 1G , and S1F).
These data demonstrate that Bmal1 and its heterodimeric partner Clock are functionally required for LSCs. Accordingly, we found that Bmal1 expression is induced by MLL-AF9 (Figure S1G) and is correlated with c-Kit, a marker of LSCs in our serial transplantation model of AML (Figures 2A, S2A , and S2B; Table S2 ).
Circadian Disruption Induces Myeloid Differentiation and Impaired Cell-Cycle Progression
We next examined the consequences of acute disruption of the circadian rhythm in AML using a small molecule. SR9011 is a potent and specific agonist of the nuclear hormone receptors Rev-Erb a and Rev-Erb b, which inhibit Bmal1 transcription via a feedback loop (Burris et al., 2013; Solt et al., 2012) . Treatment of quaternary transplant MLL-AF9 cells with SR9011 for 3 days (G) Detection of in-frame and out-of-frame mutations at the Bmal1 locus in cells expressing Cas9 and sgBmal1 by Sanger sequencing of individual clones. *p < 0.05, **p < 0.01, ***p < 0.001, determined by a two-sided Student's t test. Mean values are shown unless otherwise specified, and error bars represent ± SEM. See also Figure S1 and Table S1. in vitro resulted in a dose-dependent reduction in cell viability (EC 50 = 1.8 mM) ( Figure 2B ). In agreement with known roles of Rev-Erb a and Rev-Erb b within the circadian pathway, short duration treatment of leukemia cells with the drug resulted in decreased expression of Bmal1 and its target gene Per2 (Figure 2C ). In addition, we observed dosedependent suppression of key regulators of LSC self-renewal (HoxA9, Meis1, Ctnnb1), indicating that the circadian rhythm circuitry influences functions related to stemness ( Figure 2D ).
Consistent with these observations, we found that Clock or Bmal1 shRNAs in leukemia cells induce morphologic changes of monocytic differentiation, including decreased nuclear to cytoplasmic ratio (Figure 2E) . Using flow cytometry, we observed reduced cell surface expression of stem cell marker, c-Kit, and increased expression of myeloid differentiation markers, CD11b and Gr1 (Figures 2F, 2G, and S2C) . Additionally, leukemia differentiation following circadian gene knockdown is associated with a reduction in the percentage of actively dividing cells (S/G2/M) ) cells within the same replicate are shown. *p < 0.05, **p < 0.01, ***p < 0.001, determined by a two-sided Student's t test. Mean values are shown unless otherwise specified, and error bars represent ± SEM. See also Figure S2 and Table S2. and an increase in the fraction of cells in G0/G1 (Figures 2H and S2D) .
Murine Leukemia Cells Harbor a Functional Circadian Clock Our finding that AML cells are dependent on Clock and Bmal1 expression implies that leukemia cells, and perhaps their normal hematopoietic counterparts, harbor an intact circadian clock that regulates rhythmic gene expression. To test this possibility in primary murine leukemia cells, we used circadian reporter mice with an in-frame knockin of luciferase at the 3 0 end of the Per2 gene (Yoo et al., 2004) . We generated primary MLL-AF9 leukemias in the Per2::Luc genetic background, transplanted these leukemias to wild-type (WT) recipients entrained to a 12 hr light/12 hr dark (LD12:12) schedule, and followed the mice for 4 to 6 weeks for the development of disease (Figures S2E and S2F) . Continuous bioluminescence recordings of leukemic spleen explants from moribund mice revealed oscillations with a period of $24 hr ( Figure 3A) . Thus, murine leukemia cells have the capacity for circadian-dependent gene expression independent of the suprachiasmatic nucleus (SCN), the dominant circadian pacemaker in the CNS. Additionally, continuous bioluminescence measurements of purified Per2::Luc MLL-AF9 bone marrow cells suspended in liquid culture with cytokines confirmed that these rhythms are not dependent on an intact stromal microenvironment ( Figure S2G ).
Canonical Circadian Machinery Operates in Human AML Cells
We next examined whether the circadian circuitry is intact in human AML, as it is in murine leukemia. We found that MLL-WT (SKM-1) and MLL-rearranged (THP-1) leukemia cell lines are highly sensitive to CLOCK and BMAL1 knockdown using multiple shRNAs ( Figures 3B, S2H , and S2I). In THP-1 cells, reciprocal co-immunoprecipitation assays demonstrated a physical association between CLOCK and BMAL1, as would be expected for cells with an intact circadian mechanism ( Figure 3C ).
To define a set of CLOCK:BMAL1 targets in human AML, we performed chromatin immunoprecipitation sequencing (ChIPseq) for both TFs. We called peaks individually for CLOCK (269 peaks) and BMAL1 (9,584 peaks) in THP-1 cells and defined a high-confidence set of 140 regions associated with 229 genes bound by both factors ( Figure S2J ; Table S3A ). Pathway analysis revealed that CLOCK:BMAL1 targets are significantly enriched for genes involved in the circadian rhythm (''Circadian RhythmMammal''; MSigDB; Hyper FDR 2.09E-8), including BHLHE40/ 41, CRY1/2, NR1D1, PER1/2, and DBP ( Figure 3D ; Table S3B ). Gene ontology (GO) analysis demonstrated that high-confidence loci are involved in diverse cellular processes, including metabolism, differentiation, immune function, cell-cycle regulation, and proliferation, as reported in other tissue types (Miller et al., 2007; Richards and Gumz, 2012) (Figure 3E ). In addition, we found CLOCK:BMAL1 binding to Wnt/b-Catenin pathway genes (WNT11, FZD3, WISP1, CSNK2A3) and several genes associated with cancer (HRAS, CEBPA, ZEB1, EGLN2). E-Box sites are among the most enriched motifs in the high-confidence binding regions, consistent with the known specificity of these TFs (Weirauch et al., 2014) ( Figure 3F ; Table S3C ).
Identification of Additional Circadian Regulators in Leukemia Cells
Given evidence for binding of CLOCK:BMAL1 to multiple conserved circadian rhythm genes in human AML cells, we hypothesized that additional components of the pathway are required for LSC function. We evaluated this possibility by performing an in vivo minipool screen in murine MLL-AF9 cells with shRNAs targeting 22 genes in the canonical circadian pathway, including Clock and Bmal1 and several key regulators. This screen confirmed a role for Clock:Bmal1 and highlighted additional pathway genes (Per1/3, Cry1, Csnk1e/2a1/2b), raising the possibility that both positive and negative elements of the circadian transcriptional-translational feedback loop impact LSC function ( Figure 3G ; Table S4 ). Interestingly, a subset of the hits from this screen (Per1, Cry1) are directly bound by the Clock:Bmal1 complex and may represent essential mediators of Clock and Bmal1 activity in AML ( Figure 3G ).
Role of the Circadian Rhythm Pathway in Normal Hematopoiesis
Having established a functional requirement for Clock and Bmal1 in leukemia, we next examined their roles in normal hematopoiesis. Continuous bioluminescence studies with spleen explants from healthy Per2::Luc knockin mice entrained to LD12:12 revealed persistent oscillations with a period of $24 hr ( Figure 4A ). The circadian activity observed in these mice could reflect either rhythms in hematopoietic cells or oscillations in extra-hematopoietic cells within the spleen. We thus performed bone marrow transplantation experiments to study the rhythm specifically in HSPCs and their progeny. We harvested bone marrow from healthy Per2::Luc mice and transplanted c-Kit-enriched cells to lethally irradiated WT recipients. Continuous bioluminescence recordings of spleen explants from these mice revealed robust rhythms with a period of $24 hr ( Figure 4B) .
The presence of an intact clock in normal hematopoietic cells, in conjunction with evidence that Clock and Bmal1 are more highly expressed in HSPCs compared to differentiated cells (Figures 4C and 4D ), raises the possibility that the circadian rhythm impacts HSC function. We sought to determine the effect of circadian gene disruption on normal hematopoiesis using germline Bmal1 knockout mice that lack a functional circadian clock in all tissues, including the SCN (Bunger et al., 2000) . These mice display premature death, infertility, organ shrinkage, age-related pathologies such as cataracts, and increased reactive oxygen species, indicating that Bmal1 may be required for normal tissue stem cell homeostasis (Alvarez et al., 2008; Kondratov et al., 2006; Kondratov et al., 2009 ).
We used multi-parameter flow cytometry ( Figures S3A-S3D ) to assess Bmal1 À/À mice ( Figure S4A ) for defects in hematopoietic function and/or differentiation. We first gated lineage À , Scal + , c-Kit + (LSK) cells, with further separation based on the SLAM markers CD48 and CD150, to examine the stem cell compartment in these mice (Kiel et al., 2005) . We identified a significant reduction in the percentage of both LSK cells and long-term HSCs (LT-HSCs) in Bmal1 À/À animals compared to age-matched Bmal1 +/À controls (Figures 4E-4G ; Table S5 ). However, we did not observe a corresponding reduction in the frequency of mature myeloid or lymphoid cells in the bone marrow or spleens of
Bmal1
À/À mice, possibly due to compensatory mechanisms (Figures 4H and S4B) . Similarly, an evaluation of committed myeloid progenitor cells within the lineage À , c-Kit + (LK) fraction did not reveal significant abnormalities in the common myeloid progenitor (CMP), granulocyte monocyte progenitor (GMP), or megakaryocyte erythroid progenitor (MEP) populations ( Figure 4I ; Table S5 ). Because germline Bmal1 À/À mice have disrupted central pacemaker function, globally altered molecular and behavioral rhythms, and diverse tissue phenotypes, the stem cell finding in these mice may be related to either cell autonomous or cell non-autonomous effects. Consequently, we sought to highlight cell intrinsic mechanisms by inactivating Bmal1 in adult hematopoiesis with preservation of the circadian rhythm in the SCN and non-hematopoietic peripheral tissues. We examined the role of Bmal1 in hematopoietic cells in competitive repopulation assays using conditional knockout mice in which LoxP sites flank the critical bHLH domain of Bmal1 (Storch et al., 2007 Figures 4J and S4C-S4F ). Importantly, we did not detect differences in the frequencies of CD45.2-derived LSK cells or LTHSCs between the two groups, and no significant hematopoietic phenotypes were observed with secondary transplantation (Figures 4K , 4L, S4G, and S4H).
Consistent with these data, we found that normal murine LSK cells are resistant to Bmal1 knockdown with multiple shRNAs ( Figure S4I ). In addition, analyses of non-competitive Bmal f/f ; MxCre + mice and germline Per2 mutant (Per2 m/m ) mice (Zheng et al., 1999) did not reveal gross hematopoietic deficits ( Figures  S5A-S5I) . Collectively, these studies demonstrate that loss of Bmal1 (or Per2) in adult hematopoiesis is well tolerated.
Genetic Knockout Confirms a Leukemia-Specific Dependence on Bmal1
We used the Bmal1 conditional knockout model to evaluate the phenotypic consequences of complete loss of Bmal1 activity on leukemia maintenance. We generated murine MLL-AF9 leukemias in the Bmal1 f/f background and retrovirally transduced the cells with PIG-Cre, resulting in efficient excision ( Figure 5A ). Consistent with our shRNA and CRISPR-Cas9 results, homozygous Bmal1 loss resulted in an in vitro leukemia growth defect compared to the Bmal1 +/+ control ( Figure 5A ).
We next evaluated the effect of Bmal1 inactivation on the initiation and propagation of MLL-AF9 leukemia. We treated Bmal1 f/f ; MxCre + or Bmal1
; MxCre + animals with poly(I:C), harvested bone marrow from these mice, and confirmed excision ( Figure S5J ). C-Kit-enriched cells from both groups of mice were retrovirally transduced with MIG-MLL-AF9 and transplanted to lethally irradiated WT recipients. Although we did not observe differences in leukemia latency or overall survival between the primary transplant groups, secondary recipient mice receiving Bmal1 À/À MLL-AF9 cells lived significantly longer than mice receiving Bmal1 +/+ MLL-AF9 cells ( Figure 5B ). Thus, Bmal1 is required for disease propagation. Given these findings, in conjunction with the HSC knockout studies, we reasoned that AML cells may be differentially sensitive to circadian disruption with the Rev-Erb a/b agonist SR9011. To test this hypothesis, we measured the viability of quaternary transplant MLL-AF9 cells and normal murine LSK cells following treatment with SR9011 for 3 days in vitro. We found that murine leukemia cells are more sensitive than HSPCs to various concentrations of drug ( Figure 5C ). Similarly, SR9011 had greater activity in human AML cell lines (NOMO-1 and MOLM-13) compared to CD34
+ cord blood cells purified from healthy donors (Figure 5D ). These data indicate that myeloid leukemia cells, in contrast to normal hematopoietic cells, are highly sensitive to circadian pathway perturbation. Finally, we interrogated genomic data from The Cancer Genome Atlas (TCGA) to determine if central circadian components (CLOCK, BMAL1, PER2) are somatically disrupted in human AML (Cancer Genome Atlas Research Network, 2013) . In the 191 cases in the TCGA AML dataset, we did not identify mutations or homozygous deletions in CLOCK, BMAL1, or PER2 ( Figure S5K ), indicating that key components of the circadian circuitry are intact in AML.
DISCUSSION
Cell non-autonomous roles for the circadian rhythm in hematopoiesis are well established (Casanova-Acebes et al., 2013; Lucas et al., 2008; Mé ndez-Ferrer et al., 2008 Nguyen et al., Figure S2 and Tables S3 and S4. 2013). Our findings demonstrate a previously unrecognized role for the core circadian clock genes in AML. We found that disruption of the circadian circuitry, mediated by shRNA knockdown, targeted mutation, or genetic deletion of key TFs, impairs the growth of murine leukemia cells in vivo and human cell lines in vitro.
We evaluated the cellular mechanisms of leukemia depletion and found that circadian perturbation induces myeloid differentiation, including a reduction in cell surface expression of c-Kit, a marker of LSCs. Using the Rev-Erb a/b small molecule agonist SR9011, we identified a dose-dependent transcriptional downregulation of HoxA9, Meis1, and Ctnnb1; together, these selfrenewal TFs cooperate to induce myeloid leukemia in mice and are broadly required in multiple AML models (Heidel et al., 2012; Wang et al., 2010) . Similarly, in the skin, the circadian clock regulates the expression of stem cell self-renewal genes, including those in the Wnt/b-catenin pathway, and loss of Bmal1 results in stem cell arrhythmia in squamous cell tumors (Janich et al., 2011) . Thus, links between the circadian rhythm and self-renewal pathways may be conserved in multiple tissue contexts.
We also found that Clock and Bmal1 regulate cellular proliferation and cell-cycle progression in AML cells, consistent with phenotypes reported in other systems (Gré chez-Cassiau et al., 2008; Matsuo et al., 2003; Miller et al., 2007) . Although some studies indicate that specific clock genes may act as tumor suppressors (Fu et al., 2002) , other studies suggest a more complex relationship between the circadian rhythm and cancer (Antoch et al., 2013) . Our finding that AML cells require Clock and Bmal1 expression reinforces recent work demonstrating tumor-maintaining roles for the core circadian rhythm genes in a variety of cancers (Antoch et al., 2008; Cui et al., 2015; Elshazley et al., 2012; Janich et al., 2011; Li et al., 2013; Ozturk et al., 2009; Xiao et al., 2014) .
Furthermore, targets and binding partners of CLOCK and BMAL1 are relevant to the biology and survival of AML cells. A previous study demonstrated that CLOCK and BMAL1 form a complex with wild-type MLL1, a histone methyltransferase required for MLL-AF9 leukemia (Katada and Sassone-Corsi, 2010; Thiel et al., 2010) . This association results in cyclical H3K4 trimethylation, establishing a permissive chromatin state for genome-scale circadian transcription (Koike et al., 2012) . If the critical interaction domain of MLL1 is preserved in MLL fusions, CLOCK and BMAL1 may physically bind the MLL-AF9 complex and target it to genomic loci required for leukemia survival (Bernt et al., 2011) .
A critical feature of the circadian rhythm is oscillating gene expression in both the SCN as well as peripheral tissues. Peripheral circadian rhythms are cell-autonomous and occur in the absence of external input (Ko and Takahashi, 2006) . Using Per2::Luc knockin mice, we confirmed that MLL-AF9 leukemia cells have the capacity for rhythmic gene expression. Continuous bioluminescence recordings of leukemic tissue explants cultured in isolation demonstrated oscillations with a period of $24 hr, indicating the presence of an intact clock in primary AML cells. Rhythms were maintained with serial transplantation, and remarkably, were present in moribund mice with advanced hematologic disease.
Consistent with cyclical gene expression patterns, canonical circadian regulatory mechanisms are preserved in leukemia. ChIP-seq studies demonstrated that the CLOCK:BMAL1 complex binds to multiple known circadian pathway genes, and binding occurrs with specificity to E-box regulatory elements (Yu et al., 2006) . The MYC:MAX complex also has specificity for E-box motifs, indicating that MYC targets may display circadian-dependent regulation and contribute to cancer phenotypes. Given diverse outputs of the peripheral clock in most tissues, it is likely that a set of targets, rather than a single gene, modulates LSC function.
Although rhythmic, circadian-dependent gene expression was present in both normal cells and in leukemia, murine genetic knockout studies indicate that Bmal1 is not absolutely required for normal hematopoietic function. Interestingly, in the setting of germline loss of Bmal1, we observed a reduction in the frequency of LSK cells and LT-HSCs. Despite altered stem cell numbers, mature myeloid and lymphoid cells in both the bone marrow and spleen were grossly normal and recent work indicates that HSCs from these mice have preserved function (Ieyasu et al., 2014) . Additionally, we found that selective loss of Bmal1 in adult hematopoiesis does not significantly alter HSPC differentiation or multi-lineage repopulating activity in competitive transplantation assays.
In contrast to normal cells, leukemia cells in the MLL-AF9 model depend on Bmal1 expression. Genetic deletion of Bmal1 in established leukemias results in a competitive disadvantage. Leukemia initiation experiments demonstrated that mice and to assess the efficiency of excision, as described previously (Storch et al., 2007) . Per2::Luc knockin mice were genotyped using primers oIMR6588, oIMR6589, and oIMR6590 according to Jackson Labs protocols. All mice used in this study were maintained on a standard LD12:12 schedule with ad libitum access to food. Bone marrow and spleen harvests for murine knockout and leukemia studies were generally performed between 1 and 5 hr after the initiation of light (Zeitgeber time, ZT1 to ZT5). Control and experimental cohorts were harvested at the same time of day.
Quaternary Transplant MLL-AF9 Leukemia Model GMPs were isolated from the bone marrow of Actin-dsRed mice, as described previously (Krivtsov et al., 2006) . GMPs were spinfected twice (2,500 rpm, 90 min, 37 C) with MSCV-MLL-AF9-Neo retrovirus in SFEM (Stem Cell Technologies) supplemented with murine IL3 (mIL3, 10 ng/ml, Peprotech), murine IL6 (mIL6, 10 ng/ml, Peprotech), and murine SCF (mSCF, 10 ng/ml, Peprotech), followed by transplantation to lethally irradiated WT recipients. After disease onset, leukemic spleen cells were harvested and subsequently transplanted to sublethally irradiated secondary recipients. Two additional rounds of transplantation resulted in the generation of quaternary transplant leukemias with high penetrance and short disease latency . Flow cytometry was performed using antibodies for the lineage markers CD3, CD4, CD8, B220, CD19, IL7R, and Ter119 (Caltag), c-Kit (17-1172-83, eBioscience), Sca-1 (11-5981-82, eBioscience), CD34 (11-0341-85, eBioscience), and CD16/32 (25-0161-82, eBioscience).
Isolation of Leukemia Stem Cells
The long bones and hips of moribund quaternary transplant leukemic mice were harvested, cleaned, crushed, and sequentially passed through 100 mM and 70 mM filters (Falcon). Following red blood cells lysis (QIAGEN), leukemic bone marrow cells were stained with APC-conjugated anti-c-Kit (clone 2B8; eBioscience) and Hoechst 33258 (H21491, Invitrogen) in PBS with 2% FBS (Omega). LSC-enriched populations were isolated by sorting Hoechst ciently-enriched for leukemia-initiating cells, as described previously Miller et al., 2013) . Quaternary transplant leukemia cells were used for experiments presented in Figures 1A-1G , 2B-2H, 3G, and 5C.
ChIP-Seq
ChIP-seq was performed as previously described (Kowalczyk et al., 2012 ) with minor modifications. Specifically, THP-1 cells were fixed in 2 mM EGS (Thermo Scientific) for 30 or 60 min followed by 1% formaldehyde for 30 or 15 min at room temperature (RT), respectively. Chromatin was sonicated to a size <500 bp and then incubated overnight with either anti-Clock IgG (ab3517, Abcam) or anti-Bmal1 IgG (ab3350, Abcam). ChIP-seq libraries were prepared through the process of DNA end-repair (Epicenter), A-base addition, and adaptor ligation using indexed Illumina adaptors followed by enrichment PCR. All enzymatic steps were carried out using enzymes from New England Biolabs. Final libraries were pooled, size selected, and sequenced on HiSeq2500 with 25 paired-end reads.
ChIP-Seq Data Analysis
Paired-end reads for both ChIP and input samples were mapped to the hg19 version of the human genome using Bowtie 2 (Langmead and Salzberg, 2012) , only keeping read pairs that map uniquely to the genome. Peaks were called using findPeaks from the Homer suite (v4.7.2) (Heinz et al., 2010) with ''-style factor -fdr 0.01 -LP 0.01 -P 0.1'' parameters and using input data as background. The intersection of peaks for CLOCK and BMAL1 was used to define a high-confidence set of binding sites. Identification of target genes associated with these binding sites and functional enrichment analysis were completed using GREAT (v2.0.2) (McLean et al., 2010) . H3K4me3 peaks (Sequence Read Archive [SRA]: ERS148524) were set as background to control for activity/inactivity of genes. We identified 269 peaks associated with 406 genes for CLOCK and 9,584 peaks associated with 8,027 genes for BMAL1. Focusing on the intersection of CLOCK and BMAL1 peaks, we identified 140 binding sites associated with 229 genes. Motif analysis of high-confidence sites was performed using RSAT peak-motifs (Thomas-Chollier et al., 2012) . Gene ontology analysis (Ashburner et al., 2000) was completed using the GO Slim web portal (http://go.princeton.edu). ChIP-seq data presented in this study may be accessed on GEO (http://www.ncbi.nlm.nih.gov/geo) with GEO: GSE70686.
Statistics
Kaplan Meyer analysis (Mantel-Cox test) and EC 50 calculations were completed using GraphPad Prism 6. Statistical analysis was completed using R (http://www.r-project.org) or Excel (Microsoft) software. Mean values are shown (unless otherwise specified) and error bars represent SEMs. Flow cytometry gating and MFI analysis were completed using FlowJo 7.6.1 software. Statistical significance was determined using a two-sided Student's t test (*p < 0.05, **p < 0.01, ***p < 0.001). Detailed descriptions of additional experimental and analytical methods are included in the Supplemental Experimental Procedures.
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